Allogene Total Stockholder Equity vs Retained Earnings Analysis
ALLO Stock | USD 2.16 0.03 1.37% |
Allogene Therapeutics financial indicator trend analysis is way more than just evaluating Allogene Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allogene Therapeutics is a good investment. Please check the relationship between Allogene Therapeutics Total Stockholder Equity and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
Total Stockholder Equity vs Retained Earnings
Total Stockholder Equity vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allogene Therapeutics Total Stockholder Equity account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.
The correlation between Allogene Therapeutics' Total Stockholder Equity and Retained Earnings is -0.71. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Allogene Therapeutics, assuming nothing else is changed. The correlation between historical values of Allogene Therapeutics' Total Stockholder Equity and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Allogene Therapeutics are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Stockholder Equity i.e., Allogene Therapeutics' Total Stockholder Equity and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.71 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Allogene Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 792.18, while Selling General Administrative is likely to drop about 61.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 1.7M | 4.6M | 14.8M | 15.5M | Net Interest Income | 1.7M | 4.6M | 14.8M | 9.2M |
Allogene Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Allogene Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Allogene Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 717.8M | 1.2B | 1.0B | 817.1M | 642.8M | 820.0M | |
Other Current Liab | 23.8M | 42.0M | 34.7M | 33.7M | 24.3M | 27.6M | |
Total Current Liabilities | 33.1M | 94.3M | 48.2M | 54.5M | 37.1M | 46.6M | |
Total Stockholder Equity | 629.0M | 1.1B | 916.4M | 665.9M | 512.2M | 708.1M | |
Net Tangible Assets | 628.9M | 1.1B | 916.4M | 665.9M | 765.8M | 732.1M | |
Retained Earnings | (396.1M) | (646.3M) | (903.3M) | (1.2B) | (1.6B) | (1.5B) | |
Accounts Payable | 9.3M | 10.4M | 10.3M | 13.9M | 5.9M | 9.7M | |
Cash | 588.9M | 1.0B | 809.5M | 576.5M | 83.2M | 79.0M | |
Non Current Assets Total | 173.2M | 382.7M | 229.2M | 288.3M | 183.7M | 245.6M | |
Non Currrent Assets Other | 8.9M | 14.6M | (322.1M) | 32.7M | 16.9M | 17.7M | |
Common Stock Total Equity | 121K | 124K | 140K | 142K | 163.3K | 121.7K | |
Common Stock Shares Outstanding | 101.1M | 120.4M | 135.8M | 143.1M | 156.9M | 125.7M | |
Short Term Investments | 355.4M | 644.6M | 284.0M | 455.4M | 365.5M | 388.4M | |
Non Current Liabilities Total | 55.7M | 53.9M | 74.1M | 96.7M | 93.5M | 65.2M | |
Other Stockholder Equity | 1.0B | 1.7B | 1.8B | 1.9B | 2.1B | 1.4B | |
Total Liab | 88.8M | 148.2M | 122.2M | 151.2M | 130.6M | 111.8M | |
Net Invested Capital | 629.0M | 1.1B | 916.4M | 665.9M | 512.2M | 708.1M | |
Long Term Investments | 63.2M | 204.2M | 352.2M | 72.0M | 3.6M | 3.5M | |
Total Current Assets | 544.6M | 845.1M | 809.5M | 528.8M | 459.1M | 574.4M | |
Net Working Capital | 511.5M | 750.8M | 423.1M | 474.3M | 422.0M | 474.6M | |
Common Stock | 124K | 140K | 142K | 144K | 169K | 136.1K | |
Short Long Term Debt Total | 51.3M | 53.8M | 69.9M | 95.1M | 95.1M | 73.3M | |
Other Liab | 4.4M | 3.1M | 4.1M | 1.6M | 1.4M | 1.3M | |
Property Plant And Equipment Net | 100.9M | 160.1M | 181.0M | 196.4M | 163.2M | 154.6M | |
Net Debt | (537.5M) | (978.3M) | (739.6M) | (481.3M) | 12.0M | 12.6M | |
Other Assets | 8.9M | 263.9M | 16.1M | 16.9M | 19.4M | 18.4M | |
Cash And Short Term Investments | 588.9M | 1.0B | 809.5M | 576.5M | 448.7M | 556.9M | |
Net Receivables | 2.4M | 2.8M | 6M | 3.3M | 1.7M | 2.6M | |
Liabilities And Stockholders Equity | 717.8M | 1.2B | 1.0B | 817.1M | 642.8M | 695.7M | |
Capital Lease Obligations | 51.3M | 53.8M | 69.9M | 101.1M | 95.1M | 74.4M | |
Inventory | (60.7M) | (207.0M) | (20.0M) | (62.5M) | (71.8M) | (75.4M) | |
Other Current Assets | 14.0M | 10.6M | 8.0M | 11.5M | 10.4M | 11.0M | |
Property Plant And Equipment Gross | 56.4M | 160.1M | 123.0M | 233.3M | 214.3M | 145.9M | |
Accumulated Other Comprehensive Income | 1.1M | 268K | (2.6M) | (9.9M) | (955K) | (1.0M) | |
Capital Stock | 124K | 140K | 142K | 144K | 169K | 154K | |
Non Current Liabilities Other | 4.4M | 53.9M | 74.1M | 1.6M | 5.2M | 4.9M | |
Property Plant Equipment | 100.9M | 118.8M | 123.0M | 196.4M | 225.9M | 127.8M |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
0.59 | DYAI | Dyadic International | PairCorr |
0.54 | ESPR | Esperion Therapeutics | PairCorr |
0.5 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.